We assessed the impact on survival of angiogenesis and inflammation-related factors, particularly LDH serum levels, platelet, neutrophil and lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR), in metastatic colorectal cancer patients receiving regorafenib monotherapy.
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management
SCARTOZZI, MARIO;
2015-01-01
Abstract
We assessed the impact on survival of angiogenesis and inflammation-related factors, particularly LDH serum levels, platelet, neutrophil and lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR), in metastatic colorectal cancer patients receiving regorafenib monotherapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
OncotargetREGORAFENIB.pdf
accesso aperto
Tipologia:
versione editoriale (VoR)
Dimensione
1.55 MB
Formato
Adobe PDF
|
1.55 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
